Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20369389 | 1.00 | ALOX15 (0.37) | ALOX15ALOX12HIF1AEPAS1OPRD1 | |
| SCHEMBL20369816 | 0.81 | ALOX15 (0.55) | ALOX15ALOX12OPRD1OPRK1TAAR1 | |
| SCHEMBL18375210 | 0.81 | ALOX15 (0.55) | ALOX15ALOX12OPRD1OPRK1TAAR1 | |
| SCHEMBL18375360 | 0.81 | ALOX15 (0.36) | ALOX15ALOX12HIF1AEPAS1MAPK14 | |
| SCHEMBL20369400 | 0.81 | ALOX15 (0.36) | ALOX15ALOX12HIF1AEPAS1MAPK14 | |
| SCHEMBL19143726 | 0.77 | ALOX15 (0.39) | ALOX15ALOX12HIF1AEPAS1TAAR1 | |
| SCHEMBL20362259 | 0.76 | ALOX15 (0.38) | ALOX15ALOX12HIF1AEPAS1TAAR1 | |
| SCHEMBL18375361 | 0.76 | ALOX15 (0.38) | ALOX15ALOX12HIF1AEPAS1TAAR1 | |
| SCHEMBL12463708 | 0.76 | SLC7A5 (0.47) | ALOX15HIF1A | |
| SCHEMBL23612453 | 0.75 | PARP1 (0.42) | ALOX15ALOX12HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3319444-B1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | US | disclosed |
| US-10702498-B2 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702498-B2 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-03-14 | — | — | US | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2017007695-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | OPRM1, OPRK1, OPRD1 | ALOX15 724/4885ALOX12 649/4885HIF1A 1697/4885 |
| US-10702498-B2 | MU opioid receptor modulators | OPRM1, OPRK1, OPRD1 | ALOX15 724/4885ALOX12 649/4885HIF1A 1697/4885 |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ALOX15 724/4885ALOX12 649/4885HIF1A 1697/4885 |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ALOX15 724/4885ALOX12 649/4885HIF1A 1697/4885 |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ALOX15 724/4885ALOX12 649/4885HIF1A 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.